1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNeuroscience Consortium is sponsored by Massachusetts Life Sciences Center. This program funds pre-clinical research focused on understanding Alzheimer's and neurodegenerative diseases at Massachusetts research institutions.
Get alerted about grants like this
Get emailed when new opportunities from “Massachusetts Life Sciences Center” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Neuroscience Consortium - MLSC The Neuroscience Consortium funds pre-clinical neuroscience research at Massachusetts academic and research institutions. The MLSC in collaboration with Alzheimer Disease Research Center at Massachusetts General Hospital brings together company partners with researchers focused on understanding Alzheimer’s and neurodegenerative diseases to further research and collaboration in the space.
Companies that have participated in the Consortium include AbbVie, Biogen, Celgene, General Electric, Lundbeck, Merck, Novartis, and Sunovion Pharmaceuticals (Consortium Members). Nearly $10 million has been committed by consortium members to fund research through this program. The consortium thrives off both commitments from biotech companies and applications for innovative translational research.
Every year Consortium Members pool their resources to fund the identification and validation of novel targets for the symptomatic treatment and modification of these chronic and debilitating neurological diseases. It is required all proposals be anchored in recognized human disease genetics and pathophysiology, or within pathways of known relevance to human disease, and should be translational, rather than exploratory.
Examples of such proposals might include research that: Confirms or refutes the involvement of a particular pathway or mechanism in human disease; Identifies new molecular targets, or strengthens the case for a potential target, or rules out a suspected target; Establishes new and improved animal models of human disease in the identified focus areas, with established face and/or construct validity; Develops a method for manipulating or measuring a pathway of known human pathological relevance; or Identifies or validates a biomarker than can be used for drug discovery and/or development.
Applications for the current round of funding will be open from May 18, 2026 to Aug. 31, 2026. Please submit your application using this link .
Companies that are interested in becoming a Consortium Members should contact MLSC staff to discuss further. Please contact neuroscience@masslifesciences. com .
Launched in 2013, the consortium originally adopted a broad interest in neurological diseases with a focus on neurodegenerative and neuroinflammatory diseases. Following multiple rounds of proposals, a collective focus on Alzheimer’s Disease emerged and now the consortium spends its time and effort on understanding and developing novel solutions for AD.
Since inception, the program has garnered nearly $10 million in industry commitments and funded the work of more than 40 Principal Investigators in Massachusetts. Through the work of this program, public resources for neuroscience and Alzheimer’s researchers have been generated.
More information on these resources can be found here: Alzheimer DataLENS provides information on hypothesis-driven and data driven research, allowing neuroscientists to share, browse and visualize comprehensive results from bioinformatics analysis of public omics datasets. It also serves as a tool to organize and share results from MassCATS investigations.
Our team is happy to discuss either joining the consortium as a company Consortium Member or applying as a Massachusetts-based researcher. To connect with MLSC staff, please contact neuroscience@masslifesciences. com .
Women’s Health Initiative Transforming Health Care in Massachusetts
According to the current listing, eligibility includes: Massachusetts research institutions. Confirm the full requirements in the official notice before applying.
Applications for Neuroscience Consortium are due August 31, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Neuroscience Consortium is funded by Massachusetts Life Sciences Center. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Massachusetts. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Awards slashed by half, life sciences applicants rejected at 95%, and the White House steering which fields get funded. How the GRFP went from funding the person to funding the priority.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read article